Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
October 5, 2009- Carol Greider, Ph.D., 48, one of the world’s pioneering researchers on the structure of chromosome ends known as telomeres, today was awarded the 2009 Nobel Prize in Physiology or Medicine by the Royal Swedish Academy of Sciences. The Academy recognized her for her 1984 discovery of telomerase (ta-LAW-mer-ace), an enzyme that maintains the length and integrity of chromosome ends and is critical for the health and survival of all living cells and organisms.
Greider (pronounced grEYE-der), the Daniel Nathans Professor and Director of Molecular Biology and Genetics in the Johns Hopkins Institute for Basic Biomedical Sciences, shares this year’s prize with Elizabeth Blackburn, a professor of biochemistry and biophysics at the University of California, San Francisco, and Jack Szostak, Ph.D., of Harvard Medical School, who discovered that telomeres are made up of simple, repeating blocks of DNA building blocks and that they are found in all organisms. Greider, Blackburn and Szostak shared the 2006 Albert Lasker Award for Basic Medical Research for this work.
“Carol’s profoundly important work, its impact on science and its increasing implications for human health exemplify the Johns Hopkins mission in advancing knowledge for the sake of our world,” says Edward D. Miller, M.D., Dean and CEO of Johns Hopkins Medicine. “We are pleased that the Nobel Foundation has chosen to honor her, and we offer her our heartiest congratulations.”
Considered the most prestigious award in the world, the Nobel Prize has been awarded for achievements in physics, chemistry, physiology or medicine, literature and peace since 1901 by the Nobel Foundation in Stockholm, Sweden. Drs. Greider, Blackburn and Szostak each will receive a medal and diploma and will share a cash award of 10 million Kroner ($1.4 million USD) at a ceremony in Stockholm on Dec. 10.
"This is a wonderful moment," says Johns Hopkins University President Ron Daniels, "not only for Dr. Greider but also for all of us here at Johns Hopkins who share in her passion for discovery and her zeal for putting knowledge to work for the good of humanity. We are thrilled by this magnificent accomplishment of Carol and her colleagues and even more so by the implications of her continuing work for our understanding of such complex problems as cancer and aging. Carol has advanced scientific knowledge immeasurably, but she remains unsatisfied and wants to know more. That is the Johns Hopkins way."
Each time a cell divides, its chromosomes become a little shorter. As cells age, their telomeres shorten. The consequent loss of telomere function will cause some cells to stop dividing or die and others to undergo chromosome rearrangements that can lead to cancer.
Greider, Blackburn and Szostak performed their groundbreaking investigations in the late 1970s and the 1980s. Blackburn showed that simple, repeated DNA sequences make up chromosome ends and, with Szostak, established that these repeated sequences stabilize chromosomes and prevent them from becoming damaged. Szostak and Blackburn predicted the existence of an enzyme that would add the sequences to chromosome termini.
While a graduate student with Blackburn, who was then a member of the faculty at UC Berkeley, Greider tracked down the enzyme telomerase. She later determined that each organism's telomerase contains an RNA component that serves as a template for the creature’s particular telomere DNA repeat sequence. In addition to providing insight into how chromosome ends are maintained, Blackburn, Greider and Szostak’s work laid the foundation for studies that have linked telomerase and telomeres to human cancer and age-related conditions.
A delighted Greider thanked the Nobel Foundation for the award and emphasized that the recognition highlights the value of “discoveries driven by pure curiosity. We had no idea when we started this work that telomerase would be involved in cancer, but were simply curious about how chromosomes stayed intact.
“What intrigues basic scientists like me is that any time we do a series of experiments, there are going to be three or four new questions that come up when you think you’ve answered one. Our approach shows that while you can do research that tries to answer specific questions about a disease, you can also just follow your nose.”
Working with a single-celled, pond-dwelling organism called Tetrahymena, Greider said these organisms – rather than primates or humans – were the best test system because Tetrahymena contain “more like 40,000 chromosomes, compared to our 23 pairs” and thus have far more chromosome ends to study.
“The most far-reaching discoveries are the product of basic research,” says Stephen Desiderio, M.D., Ph.D., director of the Institute for Basic Biomedical Sciences at Johns Hopkins. “We are thrilled that Carol is being recognized for her work, which reminds us that science is most powerful when it is driven by curiosity.”
Education and Career Path
Carol Greider, 48, grew up in Davis, Calif., where her father was a physicist at the University of California. Greider credits her parents for her decision to go into science, and her father for influencing her attitude about academic science.: “My father would talk about academic freedom and the importance of liking what you do. He would say, ‘You can do whatever you want, but you have to like whatever you do.’”
Greider graduated from the University of California, Santa Barbara, with a B.A. in biology in 1983 and earned a Ph.D. in molecular biology in 1987 from the University of California, Berkeley. She worked at Cold Spring Harbor Laboratory on Long Island, N.Y., from 1988 to1997, first as a postdoctoral fellow, then an associate investigator. She moved to Johns Hopkins in 1997.
While at Cold Spring Harbor, Greider, working with Calvin Harley at McMaster University, realized that, unlike most cells in the adult human body, cancer cells contain active forms of telomerase that enable cells to keep dividing by maintaining the length of their chromosome ends. Together, in 1990, they provided early evidence that telomere length was related to cellular aging. They found that telomerase is activated in cancer cells, which allows these cells to bypass cellular senescence and continue growing as immortalized cells.
The two researchers began to imagine a treatment for cancer in which the telomerase could be inhibited long enough to wipe out the telomeres in the malignant cells. This would trigger death in the cancer cells but not in normal ones with their longer telomeres.
Subsequent work using cultured human cells and mice genetically engineered to lack the gene for telomerase confirmed that inhibition of telomerase can limit cancer cell division and tumor production.
Greider continues to study the role of telomeres in DNA damage and cell death. Recently, she and her colleagues developed a mouse model for a rare, inherited disorder related to stem cell failure — called dyskeratosis congenita — that is caused by mutations in telomerase. People with dyskeratosis congenita cannot maintain the telomerase in their bone marrow and eventually die of bone marrow failure. “Suddenly, the studies that we had done on the consequences of telomerase loss were pertinent to this disease,” Greider says. “It’s another example of curiosity-driven research ending up having a direct medical implication.”
Greider is currently working on mouse models she helped develop to understand how telomerase may play a role in both cancer and stem cell failure. This might lead to a clearer link between aging and telomeres, she says. “I don’t believe that aging is going to be a matter of just one thing, that there’s going to be one gene that controls all of aging. I think there are going to be multiple different failures, and that the loss of stem cells can play a role in a number of them.”
“Carol Greider’s profoundly important work, its impact on science and its increasing implications for human health exemplify the Johns Hopkins mission in advancing knowledge for the sake of our world,” says Edward D. Miller, M.D., the dean of medical faculty and CEO of Johns Hopkins Medicine. “We are pleased that the Nobel Foundation has chosen to honor her, and we offer her our heartiest congratulations.”
NIGMS director Jeremy M. Berg, Ph.D., adds: “Driven by curiosity, Dr. Greider and her colleagues answered fundamental questions about a basic biological process now known to be involved in cancer and cellular aging. Their work has been an important breakthrough for many fields and offers a classic example of how basic, non-disease-targeted research can illuminate our understanding of health and disease in unforeseen ways.” Prior to Berg’s appointment at NIGMS, he directed the Institute for Basic Biomedical Sciences at Johns Hopkins where he served on the faculty from 1986-2003.
Hi-Resolution Photos Available for Download:
On the Web:
More information about Carol Greider:
Molecular Biology and Genetics at the Johns Hopkins University School of Medicine:
The Johns Hopkins Institute for Basic Biomedical Sciences
Other useful links:
Media Contacts: Audrey Huang 443-838-3378; firstname.lastname@example.org
Christen Brownlee 443-838-3386; email@example.com
John Lazarou, 410-707-3116; firstname.lastname@example.org
Beth Simpkins, 443-838-0504; email@example.com